欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (4): 438-440.

• 研究原著 • 上一篇    下一篇

紫杉醇与环磷酰胺分别联合铂类药治疗卵巢癌的对比研究

李从铸, 翟玉霞1, 黄萍, 周莉, 徐岚2, 李燕   

  1. 汕头大学医学院附属肿瘤医院妇瘤科, 1超声科, 2附属一院妇产科, 汕头515031, 广东
  • 收稿日期:2003-08-19 修回日期:2004-01-22 出版日期:2004-04-26 发布日期:2020-11-20
  • 通讯作者: 李从铸, 男, 医学硕士, 副主任医师, 主要从事妇科肿瘤临床研究。Tel:0754-8555844-4077 E-mail:licongzh@21cn.com

Comparison of paclitaxel containing platinum and cyclophosphamide containing platinum chemotherapy in women with advanced epithelial ovarian cancer

LI Cong-Zhu, ZHAI Yu-Xia1, HUANG Ping, ZHOU Li, XU Lan2, LI Yan   

  1. Department of Women Cancer, 1Department of Ultrasound, the Affiliated Cancer Hospital, 2Department of Gynaecology and Obstetrics, the First Affiliated Hospital, Medical College of Shantou University, Shantou 515031, Guangdong, China
  • Received:2003-08-19 Revised:2004-01-22 Online:2004-04-26 Published:2020-11-20

摘要: 目的:比较紫杉醇联合铂类药物(TP 方案) 与环磷酰胺加铂类药物(CP 方案) 治疗Ⅲ、Ⅳ期卵巢上皮癌的疗效。方法:化疗方案每一疗程采用2 d 疗法, 每种药物d 1 或d 2 给药, 采用大剂量单次给药。对24 例Ⅲ、Ⅳ期卵巢上皮癌给予TP 方案化疗:紫杉醇剂量为135 mg·m-2, 溶于5 %GS 500 ml 中,静滴, 3 h, d 1;顺铂(DDP) 75 mg·m-2, d 2(或卡铂按AUC =5 计算所得的剂量), 前3 ~ 4 个疗程采用腹腔给药, 以后均静脉给药。30 例对照组病人采用环磷酰胺加铂类药为主的CP 方案。环磷酰胺(CTX)600 mg·m-2, 静注, d 1;阿霉素(ADM) 40 ~60 mg·m-2, 静注, d 1;长春新碱(VCR) 2 mg, 静注,d 1;DDP 60 ~ 80 mg·m-2 (或卡铂, 剂量按AUC =5 计算) 。铂类药物用药时间、途径及水化均与TP 方案相同。结果:TP 方案化疗组CR 为8 例, PR 为10例, 总有效率为75 %;CP 方案对照组CR 4 例, PR 8例, 总有效率为40 %, TP 方案化疗组有效率显著高于CP 方案化疗组(P <0.05) 。TP 治疗组中位生存期为41.5 个月, 高于CP 对照组的32.6 个月(P <0.01) 。结论:TP 方案治疗Ⅲ、Ⅳ期卵巢上皮癌疗效显著优于CP 方案。

关键词: 卵巢肿瘤, 紫杉醇, 顺铂, 卡铂, 药物疗法

Abstract: AIM: To compare the therapeutic effect of paclitaxel containing platinum (cisplatin or carboplatin) and cyclophosphamide containing platinum chemotherapy in women with epithelial ovarian cancer.METHODS: 24 cases with advanced epithelial ovarian cancer after initial surgery received paclitaxel and cisplatin or carboplati.Paclitaxel (135 mg·m-2, over a period of 3 hours) was administered iv once every 3 to 4 weeks, in comparison with those 30 cases treated with “CAP ” or “CVP” regimen.RESULTS: The overall median survival time was significantly longer in the paclitaxel-platinum group than that in the cisplatin-cyclophosphamide group (median 41.5 vs 32.6 mon, P <0.01).Among 24 women with measurable disease, 75 percents in the “TP” group responded to the therapy, comparing with 40 percent in the “CP” group (P <0.05).CONCLUSION: Paclitaxel and platinum agent is more effective than “CP” regimen in the treatment of patients with advanced epithelial ovarian cancer.

Key words: ovarian neoplasms, paclitaxel, cisplatin, carboplatin, chemotherapy

中图分类号: